Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2017 Jul 13;7(1):5319.
doi: 10.1038/s41598-017-05464-0.

Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis

Jinxin Shi  1 , Peng Gao  1 , Yongxi Song  1 , Xiaowan Chen  1 , Yuan Li  1 , Changwang Zhang  1 , Hongchi Wang  1 , Zhenning Wang  2
Affiliations
Meta-Analysis

Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis

Jinxin Shi et al. Sci Rep. .

Abstract

Taxanes are chemotherapeutic agents commonly used to treat several cancers. However, the effects of taxanes on advanced gastric cancer (AGC) are still not clear, especially when used as a first-line treatment. This systematic review and meta-analysis aims to investigate the efficacy and safety of taxanes as a first-line treatment of AGC. The quality of our included studies was assessed using the Cochrane risk of bias tool for RCTs and NOS scale for nRCTs, and the data of the included studies was of satisfactory quality to analyze. The outcomes included overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and toxicity. Taxanes significantly improved OS (HR = 0.84, 95% CI 0.76-0.92, P = 0.0004) and had a slight effect on ORR (RR = 1.23, 95% CI 1.00-1.51, P = 0.05). However, taxanes may also increase the risks of neutropenia and leucopenia, similar to effects observed in other conventional chemotherapeutic treatments such as oxaliplatin and epirubicin. Therefore, patient characteristics including concomitant diseases, physical condition, and prior therapies should be considered before selecting taxane-based treatments for AGC.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Figure 1
Figure 1
The flow chart of studies selection.
Figure 2
Figure 2
Risk of bias graph and summary of RCTs.
Figure 3
Figure 3
Meta-analysis of the overall survival (OS). (a) Forest plots of the hazard ratio (HR) for the OS comparing Taxane with control. (b) Subgroup analysis between the adding and replacing groups of the OS. (c) Subgroup analysis between the RCT and nRCT groups of the OS.
Figure 4
Figure 4
Meta-analysis of the progression-free survival (PFS). (a) Forest plots of the hazard ratio (HR) for the PFS comparing Taxane with control. (b) Subgroup analysis between the adding and replacing groups of the PFS. (c) Subgroup analysis between the RCT and nRCT groups of the PFS.
Figure 5
Figure 5
Meta-analysis of the overall response rate (ORR). (a) Forest plots of the risk ratio (RR) for the ORR comparing Taxane with control. (b) Subgroup analysis between the adding and replacing groups of the ORR. (c) Subgroup analysis between the RCT and nRCT groups of the ORR.
See this image and copyright information in PMC

References

    1. Torre LA, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Buzzoni R, et al. Pathological features as predictors of recurrence after radical resection of gastric cancer. Br J Surg. 2006;93:205–9. doi: 10.1002/bjs.5225. - DOI - PubMed
    1. Liu Y, Feng Y, Gao Y, Hou R. Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery. Onco Targets Ther. 2016;9:1269–73. - PMC - PubMed
    1. Glimelius B, Hoffman K, Haglund U, Nyren O, Sjoden PO. Initial or delayed chemotherapy with best supportive care in advanced gastric cancer. Ann Oncol. 1994;5:189–90. doi: 10.1093/oxfordjournals.annonc.a058778. - DOI - PubMed
    1. Ochenduszko S, et al. Comparison of efficacy and safety of first-line palliative chemotherapy with EOX and mDCF regimens in patients with locally advanced inoperable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma: a randomized phase 3 trial. Med Oncol. 2015;32:242. doi: 10.1007/s12032-015-0687-7. - DOI - PMC - PubMed

Publication types

MeSH terms